Latest Articles

Publication Date
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Single-cell profiling and machine learning identify cuproptosis-related fibroblast subpopulations and fibrogenesis modulator AEBP1 in endometriosis.

Endometriosis is characterized by progressive fibrosis and limited therapeutic options. Cuproptosis, a copper-dependent form of regulated cell death, has been implicated in multiple pathological conditions, but its relevance to fibroblast-mediated …

Published: May 18, 2026, midnight
HSD11B1 suppresses ferroptosis in endometrial stromal cells through the JUND/IL-10 axis to promote endometriosis progression.

Endometriosis (EMs) is a common gynecological disorder characterized by ectopic endometrial tissue growth, leading to chronic inflammation and pelvic pain. Despite its high prevalence, the molecular mechanisms underlying EMs remain …

Published: May 18, 2026, midnight
Cancer-like Hallmarks of Endometriosis: The Role of Estrogen Signaling and Stem Cell Plasticity.

Endometriosis is a chronic estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age and characterized by ectopic endometrial-like tissue growth. Although traditionally considered a benign gynecological condition, increasing …

Published: May 18, 2026, midnight
Nuclear factor IX promotes endometriosis progression through transcriptional activation of tetraspanin-2.

Endometriosis is a benign yet aggressive disease characterized by enhanced proliferation and invasion of ectopic endometrial tissue. Identifying upstream regulators that co-regulate these processes will provide novel insights into endometriosis …

Published: May 16, 2026, midnight
NLRP1 promotes pyroptosis in endometriosis through the NF-κB signaling pathway.

Endometriosis is a prevalent gynecological disorder characterized by chronic inflammation. Pyroptosis, a type of programmed proinflammatory cell death, plays a crucial role in various inflammatory diseases. However, its specific mechanism …

Published: May 14, 2026, midnight
Gut microbiota-associated immunomodulation contributes to the protective effects of fluvastatin against endometriosis in a mouse model, accompanied by increased Akkermansia muciniphila abundance.

Endometriosis (EMs) is a chronic inflammatory disease characterized by tumor-like growth behavior and limited therapeutic options. Increasing evidence suggests that gut microbiota may contribute to EMs progression by promoting chronic …

Published: May 14, 2026, midnight
The role of the SIRT1/FOXO1 axis in regulating autophagy and inflammation in endometriosis.

Endometriosis, a common chronic gynecological disorder, involves cellular autophagy and inflammatory processes in its pathogenesis. However, the specific regulatory mechanisms of autophagy and inflammation in endometriosis remain unknown. In this …

Published: May 13, 2026, midnight
Elevated CENPA Promotes Endometrial Cancer Progression - Docwire News

Elevated CENPA Promotes Endometrial Cancer Progression Docwire News

Published: May 12, 2026, 11:41 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!